Intra Cellular Therapies reported $59.07M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 119.6M 23.54M
ALKERMES ALKS:US $ 462.36M 8.93M
Aptinyx Inc APTX:US $ 4.74M 949K
Biocryst Pharmaceuticals BCRX:US $ 81.02M 22.7M
Biogen BIIB:US $ 3946.6M 351.6M
Bristol Myers Squibb BMY:US $ 22821M 953M
Cytokinetics CYTK:US $ 66.85M 5.01M
Esperion Therapeutics ESPR:US $ 79.08M 5.73M
Gilead Sciences GILD:US $ 8558M 3052M
Halozyme Therapeutics HALO:US $ 111.69M 5.46M
Intra Cellular Therapies ITCI:US $ 59.07M 5.72M
JAZZ PHA JAZZ:US $ 737.41M 71.89M
Johnson & Johnson JNJ:US $ 43390M 1836M
Marinus Pharmaceuticals MRNS:US $ 19.54M 21.03M
Minerva Neurosciences NERV:US $ 3.25M 0.43M
Nektar Therapeutics NKTR:US $ 105.28M 20.08M
Neurocrine Biosciences NBIX:US $ 253.5M 7.7M
Novartis NVS:US $ 29807M 401M
Prothena PRTA:US 36.5M 3.04M
Supernus Pharmaceuticals SUPN:US $ 284.56M 30.82M
United Therapeutics UTHR:US $ 292.6M 12.8M
Vanda Pharmaceuticals VNDA:US $ 90.74M 16.32M